Pharmaceutical sector M&A resurgence in 2018

31 December 2018

After a quiet year in 2017 for mergers and acquisitions (M&A) in the global pharmaceutical, biotechnology and generics, there was significant upturn in 2018.

The total number of M&A deal announcements tracked by The Pharma Letter in 2019 came to 111, compared with 101 in 2017, but still below the boom years of 130 in 2016 and 155 in 2015. Within this total, there were 26 deals with a potential value of over $1 billion, versus 15 in 2017.

A significant portion of the acquisitions announced in 2018, as usual, did not disclose financial terms. However, the Evaluate Group estimates that, for the first nine months of the year, the value of M&A activity had reached $124.7 billion, compared to just $79 billion in the whole of 2017 and $107.2 billion in 2016. For its part, Informa Pharma Intelligence has estimated that about $265 billion in M&A activity had taken place in biopharma during 2018, a rise of 26% on 2017.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK